Efficacy Study of Nifedipine Controlled-Release Tablets (Xin Ran) to Treat Early Morning Blood Pressure and Central Arterial Pressure

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 244 participants.

Also called NCT02357615

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 244 participants (planned count) (from the registry)
Sponsor
Shanghai Shyndec Pharmaceutical Co., Ltd. (from the registry)
Registry
  • NCT NCT02357615
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02357615. Randomized; no masking; primary purpose treatment. Start 2014-12 (registry gives no type); primary completion 2015-06 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy Study of Nifedipine Controlled-Release Tablets (Xin Ran) to Treat Early Morning Blood Pressure and Central Arterial Pressure
Condition
Essential Hypertension
Intervention (Drug)
nifedipine CR tablets (Xin Ran)
Intervention (Drug)
Adalat
Lead sponsor
Shanghai Shyndec Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct02357615
Content hash
05fc2aa4786a30b942f4304be18bd38d9bf3ec9fb4c7260ebc30441a900acec1